New EAS Consensus Statement on FH: Improving the care of FH patients

Atherosclerosis

Volumn 231, Issue 1, 2013, Pages 69-71

  Stock, Jane ^a  

^a European Atherosclerosis Society   (Sweden)

Author keywords

Coronary artery disease; Dyslipidaemia; EAS consensus paper; Familial hypercholesterolaemia; FH underdiagnosed; LDL cholesterol; Recommendations

Indexed keywords

LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN;

ATHEROSCLEROSIS; AWARENESS; CLINICAL EXAMINATION; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SCREENING; HUMAN; LIPID BLOOD LEVEL; MEDICAL HISTORY; NOTE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCREENING;

CORONARY ARTERY DISEASE; DYSLIPIDAEMIA; EAS CONSENSUS PAPER; FAMILIAL HYPERCHOLESTEROLAEMIA; FH UNDERDIAGNOSED; LDL CHOLESTEROL; RECOMMENDATIONS;

ADOLESCENT; ADULT; CHILD; CHOLESTEROL, LDL; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIFE STYLE;

EID: 84885363492     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.035     Document Type: Note

References (12)

1. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969, 2:1380-1382.
2. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. European atherosclerosis society consensus panel. Eur Heart J 2013, Epub ahead of print August 15, 2013.
3. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolaemia. The metabolic and molecular basis of inherited disease 2001, vol. III:2863-2914. McGraw Hill, New York. 8th ed.
4. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. JClin Endocrinol Metab 2012, 97:3956-3964.
5. Rader D.J., Cohen J., Hobbs H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. JClin Invest 2003, 111:1795-1803.
6. Civeira F., Ros E., Jarauta E., et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008, 102:1187-1193.
7. Palacios L., Grandoso L., Cuevas N., et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 2012, 221:137-142.
8. Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a crosssectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012, 5:354-359.
9. Starr B., Hadfield S.G., Hutten B.A., et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008, 46:791-803.
10. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:3-46.
11. Robinson J.G., Goldberg A.C. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. JClin Lipidol 2011, 5:S18-S29.
12. Schuff-Werner P., Fenger S., Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl 2012, 7:7-14.